Clinical Trial Update: Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma [Phase 2]

View source ↗

Summary

Phase 2 trial of bevacizumab plus everolimus in refractory progressive intracranial meningioma was terminated with posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracranial Meningioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Intracranial Meningioma | Phase 2 | Status: TERMINATED | Results posted: 2015-06-04